This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Enzymatic Hydrolysis and Biological Activity of Oligonucleotides Containing 5-Substituted Pyrrmidine Bases

L. Ötvös^a; J. Sági^a; Gy. Sági^a; A. Szemzõ^a; F. D. Tóth^b; A. Jeney^c

^a Chemical Research Center, Institute of Chemistry, Hungarian Academy of Sciences, Pusztaszeri st, Hungary ^b Institute of Microbiology, University Medical School of Debrecen, Hungary ^c I. Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Üllõi st., Hungary

To cite this Article Ötvös, L., Sági, J., Sági, Gy., Szemző, A., Tóth, F. D. and Jeney, A.(1999) 'Enzymatic Hydrolysis and Biological Activity of Oligonucleotides Containing 5-Substituted Pyrrmidine Bases', Nucleosides, Nucleotides and Nucleic Acids, 18:6,1665-1666

To link to this Article: DOI: 10.1080/07328319908044816 URL: http://dx.doi.org/10.1080/07328319908044816

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ENZYMATIC HYDROLYSIS AND BIOLOGICAL ACTIVITY OF OLIGONUCLEOTIDES CONTAINING 5-SUBSTITUTED PYRIMIDINE BASES.

L.Ötvös¹, J. Sági¹, Gy. Sági^{1*}, A. Szemzõ¹, F. D Tóth² and A. Jeney³.

¹Chemical Research Center, Institute of Chemistry, Hungarian Academy of Sciences. 1025 Budapest, Pusztaszeri st. 59-67., Hungary. ²Institute of Microbiology, University Medical School of Debrecen. 4012 Debrecen, Nagyerdei blvd. 98., Hungary. ³I. Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, 1085 Budapest, Üllői st. 26., Hungary.

ABSTRACT. Two series of alternating ODNs containing 5-n.alkyl-, alkenyl- and alkynyl-dU and -dC units have been prepared in order to study the kinetics of their hydrolysis by SV PDE and human serum, respectively. Both in (r⁵dUpdA)₁₀ and (r³dCpdG)₆ series the rate of hydrolysis decreased with increasing length of side-chain. Replacement of thymidines by 5-hexynyl-dU in different antisense oligomers resulted in considerably higher biological activity relative to that of the thymidine-containing counterparts.

Oligonucleotides composed of natural building blocks are good substrates of extraand intracellular nucleases, which is the major obstacle in their use as potential chemotherapeutic agents [1]. Although the necessary nuclease resistance is usually attained by phosphate modifications, the most commonly used phosphorothioate antisense oligos sometimes show non-sequence-specific effects, as well [2,3]. However, certain base-modified oligonucleotides were also found to be stable against endo- and exonuclease degradation [4].

In this study we investigated the enzymatic stability of two series of modified, self-complementary oligonucleotides containing 5-n.alkyl-, (E)-5-(1-alken-1-yl)-, and 5-(1-alkyn-1-yl)-dU and -dC units, respectively. The synthesized (r⁵dUpdA)₁₀ and (r⁵dCpdG)₆ analogues were hydrolysed by snake venom phosphodiesterase (SV PDE) and human serum, respectively. In both cases the initial rate of degradation was

1666 ÖTVÖS ET AL.

determined by HPLC. We found that in the case of SV PDE the hydrolysis rate of alkyl- and alkenyl-substituted oligomers continuously decreased with increasing length of carbon side-chain up to hexyl and hexenyl analogues, which were quite resistant within the investigated periods. It may be explained by supposing that the bulky 5-substituents sterically protect the phosphate moieties against nuclease attack. Beside steric effect the thermal stability of oligonucleotides also seems to play important role in resistance to nucleases. It was confirmed by the enhanced stability of alkynyl oligomers that correlates well with their higher duplex stability [5] in addition, the shorter but still much more thermostable dCpdG analogues were found to be more resistant than the corresponding dUpdA derivatives. Total nuclease activity of human serum was lower than that of SV PDE, especially towards (r5dCpdG)6 series, where even the analogues of short side-chain (ethyl, vinyl, ethynyl) proved nearly or quite resistant.

Due to the advantageous biochemical properties mentioned above, the 5-hexynyldU was selected and incorporated into two series of antisense oligonucleotides in place biological activity. Thus, four 18-mers, of thymidines to study its effect on complementary to a mRNA region of 92 kDa type human collagenase IV, and four 20mers, targeted to splice-donor region of HIV-1 mRNA, were synthesized. Both series consisted of unmodified, base-modified, thio-modified, and base+thio-modified analogues. In the case of human collagenase inhibition —that may have great importance in cancer chemotherapy-the oligomers containing 5-hexynyl-dU have significantly lower IC50 values than their thymidine-containing counterparts. Similar results were obtained with the four anti-HIV agents, as well. Twenty days after HIV-1 infection the unmodified analogue proved practically ineffective, whereas the base- and thio-modified variants reduced the HIV-1 replication by 62 and 78%, respectively. The base+thio-modified derivative produced complete supression of virus multiplication not only after 20 days but through 4 weeks, so it can be regarded as a most promising anti-HIV agent.

REFERENCES

- [1] E. Uhlmann, A. Peyman. Chem. Rev. 1990, 90, 543-584.
- [2] J.F.Milligan et al. J.Med.Chem. 1993, 36, 1923-1937.
- [3] C.A.Stein. Chemistry & Biology 1996, 3, 319-323.
- [4] P.D.Cook. Anti-Cancer Drug Des. 1991,6, 585-607.
- [5] J.Sagi et al. Tetrahedron Lett. 1993, 34, 2191-2194.